Enrique Gutierrez, MD
Family Medicine · Kissimmee, FLNPI 1407951304
Payments from drug & device makers
Across 504 payments — averaging $79.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$20K
- AstraZeneca$12K
- Novo Nordisk$2K
- Boehringer Ingelheim$777
- Gilead$668
- Lilly USA, LLC$618
- plus $4K from 34 others
What the payments were for
- Travel & lodging$40%
- Food & beverage$8,817100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 12 | $20,261 |
| AstraZeneca | 63 | $12,255 |
| Novo Nordisk | 115 | $1,848 |
| Boehringer Ingelheim | 46 | $777 |
| Gilead | 22 | $668 |
| Lilly USA, LLC | 37 | $618 |
| Merck | 34 | $595 |
| Viiv Healthcare Company | 34 | $583 |
| Sanofi-aventis U.S. LLC | 26 | $471 |
| Pfizer | 14 | $268 |
| Bayer | 10 | $236 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $195 |
| AbbVie | 9 | $191 |
| Amarin Pharma, Inc. | 11 | $180 |
| Johnson & Johnson(2 entities) | 11 | $164 |
| Abbott | 6 | $111 |
| Exact Sciences | 3 | $78 |
| Scilex Pharmaceuticals Inc. | 4 | $70 |
| Amgen | 4 | $69 |
| Corcept Therapeutics | 3 | $59 |
| Astellas Pharma US Inc | 3 | $53 |
| Redhill Biopharma Inc. | 3 | $52 |
| EMD Serono, Inc. | 3 | $50 |
| Dexcom, Inc. | 1 | $43 |
| Novartis | 2 | $40 |
| Phadia US Inc. | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Cipher Pharmaceuticals US LLC | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Neotract Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$40,198 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 64 | $213,948 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 35 | $129,886 |
| DovatoDolutegravir Sodium/Lamivudine | 36 | $98,312 |
| JardianceEmpagliflozin | 95 | $84,059 |
| FarxigaDapagliflozin Propanediol | 60 | $55,025 |
| TrulicityDulaglutide | 39 | $45,440 |
| OzempicSemaglutide | 43 | $45,399 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $41,239 |
| JulucaDolutegravir/Rilpivirine | 12 | $39,448 |
| RybelsusSemaglutide | 22 | $36,829 |
| EliquisApixaban | 34 | $34,694 |
| MounjaroTirzepatide | 19 | $33,595 |
| LinzessLinaclotide | 29 | $25,175 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 12 | $22,715 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $19,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $668 | $343,83499 claims |
| Viiv Healthcare CompanyDovato, Juluca | $583 | $137,76048 claims |
| Boehringer IngelheimJardiance, Synjardy | $777 | $90,483106 claims |
| Novo NordiskOzempic, Rybelsus | $1,848 | $82,22865 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $618 | $79,03558 claims |
| AstraZenecaFarxiga, Brilinta | $12,255 | $60,11172 claims |
| PfizerEliquis | $268 | $34,69434 claims |
| AbbVieLinzess, Lumigan | $191 | $31,33243 claims |
| MerckDelstrigo | $595 | $22,71512 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $471 | $19,57119 claims |
| GSKArnuity Ellipta | $20,261 | $4,32711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Kissimmee
- Craig CurtisKissimmee$14.2M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.